Posted

Bridge to Life Divests Certain Assets to TransMedics

Bridge to Life Ltd. announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc., including its EVOSS heart and lung and LifeCradle [...]

Posted

ADVANCING TRANSPLANTATION TECHNOLOGIES: Bridge to HOPE Trial Demonstrates Promising Findings with Hypothermic Oxygenated Perfusion

Bridge to Life Ltd. announced results from interim analysis of its multicenter, randomized, controlled liver clinical trial presented at the 2023 American Transplant Congress (ATC).

Posted

Early Closure of Bridge to Life Ltd. HOPE Liver Trial Enrollment Affirms the Potential of Hypothermic Oxygenated Perfusion

Bridge to Life, Ltd. announced that it met positive criteria from interim analysis for early enrollment closure of its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Posted

Bridge to Life Ltd. Receives Investigational Device Exemption Approval from the FDA

Bridge to Life, Ltd. announced investigational device exemption approval by the U.S. FDA for its VitaSmart™ Liver Machine Perfusion System and plans to enroll the first patient in its U.S. Bridge [...]

Posted

Bridge to Life Announces First Close of $56 Million Growth Financing Led by Perceptive Advisors

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by [...]

page 1 of 2